Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly FCF Margin of 20320.0% for Q1 2026, down 1839281.0% year-over-year from N/an in Q1 2025, and down 266439.43% quarter-over-quarter from 7.62% in Q4 2025.
Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported FCF Margin for 5 consecutive years, with 20320.0% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 1839281.0% year-over-year to 20320.0%; the TTM figure through Mar 2026 stood at 167.33% (up 171947.0% YoY), while the FY2025 annual figure was 146.74%, up 178074.0% from the prior year.
- FCF Margin slipped to 20320.0% in Q1 2026 per OBIO's latest filing, from 7.62% in the prior quarter.
- Across five years, FCF Margin topped out at 7.62% in Q4 2025 and bottomed at 20320.0% in Q1 2026.
- Historically, FCF Margin has averaged 2892.7% across 5 years, with a median of 1682.46% in 2025.
- Annual changes were most pronounced in 2025 — FCF Margin jumped 538526 bps — and 2026, when it plunged 1839281 bps.
- Orchestra BioMed Holdings' FCF Margin stood at 797.64% in 2022, then plunged by 425 bps to 4187.4% in 2023, then retreated by 29 bps to 5392.89% in 2024, then surged by 100 bps to 7.62% in 2025, then sank by 266439 bps to 20320.0% in 2026.
- Business Quant data shows OBIO's FCF Margin at 20320.0% in Q1 2026, 7.62% in Q4 2025, and 1682.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -22,256.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22,256.82% |
| Mar 31, 2026 | -20,320.00% |
| Dec 31, 2025 | -7.62% |
| Sep 30, 2025 | -1,682.46% |
| Jun 30, 2025 | -1,861.36% |
| Mar 31, 2025 | -1,927.19% |
| Dec 31, 2024 | -5,392.89% |
| Sep 30, 2024 | -1,394.93% |
| Jun 30, 2024 | -1,325.58% |
| Mar 31, 2024 | -2,116.45% |
| Dec 31, 2023 | -4,187.40% |
| Sep 30, 2023 | -2,458.47% |
| Jun 30, 2023 | -1,149.40% |
| Mar 31, 2023 | -1,238.49% |
| Dec 31, 2022 | -797.64% |
| Sep 30, 2022 | -643.16% |
| Jun 30, 2022 | -2,052.62% |
| Mar 31, 2022 | -620.21% |